Biotech News

Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027

Aquestive Therapeutics (AQST)Aquestive TherapeuticsFDA / regulatory

FDA accepted the resubmission as complete and classified it as a Class 2 response Prescription Drug User Fee Act (PDUFA) goal action date set for March 16, 2027 Ex-U.S. strategy remains on track with Canadian NDS planned for Q4 2026 WARREN, N.J., Oct.

Related news

Aquestive Therapeutics

Oral Film Drug Delivery Company Aquestive Therapeutics develops medicines using proprietary film-based delivery technologies for allergic reactions and other conditions. Anaphylm Anaphylm is a postage-stamp-sized sublingual film containing a prodrug of epinephrine for severe allergic reactions, including anaphylaxis. It dissolves without...

Recent company news

Stock data

Close
3.71 USD
Market cap
493.02M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States